FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

NEULANDLAB Share Price Target

Neuland Laboratories Ltd.
Sector: Pharmaceuticals and health care
... Read more
NEULANDLAB Long Term Analysts Rating
5/5 (2 Ratings)
NEULANDLAB Share Price *
476.5 -7.4 (-1.53%)
* (quote may be delayed)

2 NEULANDLAB share price target reports by brokerages below. See what is analyst's view on NEULANDLAB share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.


You can also find NEULANDLAB share price target tomorrow or next week from NEULANDLAB discussion forum.

NEULANDLAB Share Price Forecast - Consensus
No. of reports in last year
2
No. of analysts
1
Average Consensus Forecast
777.50
Consensus Potential
37.48%

NEULANDLAB Share Price Target - Broker Reports - 2019

HDFC Securities
19-Aug-19
Price @ Call: 504.1
Target: 725
BUY
We maintain BUY on NLL following a mixed quarter. Our TP is revised to Rs 725 (14x FY21E EPS). The scale up in lucrative products like Salmeterol and Austedo remain key triggers for improvement in operational performance.
... Read more

HDFC Securities
15-Feb-19
Price @ Call: 583.15
Target: 830
BUY

NEULANDLAB Share Price Target - Broker Reports - 2018

HDFC Securities
12-May-18
Price @ Call: 793.56
Target: 1000
BUY

HDFC Securities
15-Mar-18
Price @ Call: 697.1
Target: 1065
BUY

NEULANDLAB Share Price Target - Broker Reports - 2017

AnandRathi
26-Sep-17
Price @ Call: 993
Target: 1318
BUY

NEULANDLAB Share Price Target - Broker Reports - 2016

Hem Securities
25-Aug-16
Price @ Call: 1024.1
Target: 1280
BUY

  • NEULANDLAB - Share Price Target Potential

    keyboard_arrow_down
    BrokerageTargetPotential
    HDFC Securities72533.26%
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.